Lecanemab Therapy for Alzheimer’s to Launch in Graz, Offering Hope for Slowed Disease Progression
Graz, Austria – A new era in Alzheimer’s treatment is dawning in Austria, with the imminent launch of Lecanemab antibody therapy at the LKH University Hospital in Graz.The first patient is expected to begin infusions as early as October, offering a potential, albeit modest, slowing of cognitive decline for a select group of individuals battling the devastating disease. simultaneously, the Klagenfurt Clinic is preparing to administer the treatment, anticipating a smaller cohort of eligible patients due to stringent selection criteria.
Alzheimer’s disease affects an estimated 100,000 people in Austria alone, placing an immense burden on patients, families, and the healthcare system. while not a cure, Lecanemab represents a significant advancement, becoming one of the first therapies to demonstrably impact the underlying pathology of Alzheimer’s, rather than simply managing symptoms. The drug, administered via bi-weekly infusions, targets amyloid plaques in the brain, believed to be a key driver of the disease. The arrival of this therapy in Graz marks a pivotal moment, offering a renewed sense of hope and a potential extension of quality of life for those affected.
“We already have some patients in the test procedure whether they are suitable for therapy,” explains Dr. seiler of the LKH University Hospital.Primarius Jörg Weber at the Klagenfurt Clinic notes the careful patient selection process, stating, “Due to the strict selection criteria, we expect a small number of patients to be treated.”
The therapy’s effects, while promising, are not without potential risks.Regular MRI monitoring will be crucial, as serious side effects such as brain bleeding and swelling have been observed in clinical trials. “Most of these side effects were slightly pronounced in the studies and have also receded,” Dr. Seiler assures, emphasizing the importance of precise patient selection to minimize risk. Estimates suggest that between 5 and 15 percent of all Alzheimer’s patients might potentially be eligible for Lecanemab.
Dr. seiler underscores the realistic expectations surrounding the treatment: “The new therapy does not mean healing.” However, he highlights the profound impact of even a 30 percent slowing of disease progression. “The drug brings more time to a person affected – with his relatives, with his life. And this time is priceless.” He anticipates a deeply emotional moment when the first patient receives the infusion, stating, “We take a step into a new era together.”
